UK News Archive

2018

November

Media Release / Nov 28, 2018

Novartis to move UK headquarters to London in bold move to join emerging life sciences cluster

Read More
Media Release / Nov 22, 2018

Novartis receives European licence for Luxturna®▼ (voretigene neparvovec), the first one-time gene therapy to improve visual acuity in people with rare inherited retinal disease

Read More
Media Release / Nov 01, 2018

Novartis applies to the Court of Appeal following the recent judicial review on a Clinical Commissioning Group (CCG) policy related to the routine use of an unlicensed medicine on the NHS

Read More

October

Media Release / Oct 29, 2018

Two-year head-to-head data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD

Read More
Media Release / Oct 12, 2018

Novartis appeals the High Court judicial review judgment to defend the UK’s regulatory framework

Read More

September

Media Release / Sep 25, 2018

Novartis proposes to exit Grimsby UK site by end of 2020 as part of global manufacturing network transformation

Read More
Media Release / Sep 21, 2018

Patients asked to accept unlicensed treatment to save money

Read More
Media Release / Sep 18, 2018

Alzheimer’s survey reveals nearly half of UK adults believe a cure will be developed in their lifetime

Read More
Media Release / Sep 17, 2018

Novartis’ Tafinlar® (dabrafenib) + Mekinist® (trametinib): first BRAF-targeted therapy for adjuvant treatment of most aggressive form of skin cancer now available on NHS

Read More

July

Media Release / Jul 31, 2018

Novartis receives European licence for Aimovig®▼(erenumab), the first treatment designed specifically for the prevention of migraine

Read More

Related Links